Medicare AdvantageCoverageMedium impact
MA08.151d, Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease
Independence Blue Cross·Neurology, Geriatrics, Internal Medicine +1 more·Medical Policy
Effective date
Mar 5, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.151d regarding monoclonal antibodies for Alzheimer's disease treatment has been reissued and will become effective March 5, 2025. This policy update specifically affects coverage and billing requirements for Alzheimer's treatments using monoclonal antibodies directed against amyloid.
Action Required
By March 5, 2025: Billing team must review and implement updated coverage requirements for monoclonal antibody treatments for Alzheimer's disease under Medicare Advantage plans. Access the full policy at the provided URL to understand specific billing and documentation requirements. Ensure providers are aware of any changes to prior authorization or coverage criteria.